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Abstract Using [32P]poly(Glu,Tyr) as substrate, we have 
identified, for the first time, in the rat prostatic gland a 
protein-tyrosine phosphatase activity different from that asso-
ciated with prostatic acid phosphatase. Concanavalin A-Sephar-
ose 4B was used to separate the two protein-tyrosyl phosphatases 
activities. The activity retained by the lectin had characteristics 
of the prostatic acid phosphatase. It was sensitive to inhibition by 
PNPP and the optimum pH shifted towards physiological values 
when [32P]poly(Glu,Tyr) was used as substrate. However, the 
major protein-tyrosine phosphatase activity was not retained by 
the lectin, and corresponded, at least in part, to SHPl as probed 
by the presence of the protein, its mRNA and the loss of PTPase 
activity after immunodepletion of SHPl. This enzyme is 
localized within the epithelial cells. Thus, the coexistence of 
two protein-tyrosine phosphatase activities in rat prostate, one 
associated with the acid phosphatase and the other related to 
SHPl, makes it necessary to analyze the importance of both 
activities in vivo and their possible function regarding prostatic 
cell growth and its regulation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Important cellular activities such as cell proliferation, onco-
genesis and signal transduction are regulated, in part, by the 
balance between the activities of protein-tyrosine kinases 
(PTKs) and protein-tyrosine phosphatases (PTPases) [1]. 
PTKs are notable in that they are the cytoplasmic catalytic 
portion for many growth factor receptors and the genes that 
encode them are potential oncogenes. PTPases, by contrast, 
have recently been identified. These enzymes represent a struc-
turally diverse family of transmembrane receptor-like and 
non-receptor enzymes which play a crucial role in cellular 
processes involving phosphorylation on tyrosine residues, 
such as growth and differentiation [2,3]. Typical non-receptor 
PTPases have accessory domains of varied structural motives, 
at either the N- or C-terminal end of the catalytic domain. 
Some accessory domains are related to well-characterized pro-
tein families [4]. Recently, several laboratories have identified 
a subfamily of non-receptor PTPases, including SHPl [5-8], 
Drosophila corkscrew gene product [9] and SHPTP2 [10,11]. 
These three PTPases contain two Src homology 2 (SH2) do-
mains N-terminal to their PTPase domain. SH2 domains are 
found in a variety of signal-transducing proteins and mediate 
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its association with tyrosine-phosphorylated proteins [12]. 
Thus, these PTPases may associate with activated receptor 
PTKs or substrates of these kinases. One of these PTPases, 
SHPl is predominantly expressed in hematopoietic cells, 
where it negatively regulates cell growth [13]. It is also ex-
pressed in malignant epithelial cell lines and in tissues replen-
ished from stem cells, suggesting that this enzyme may play a 
role in cellular signal transduction of non-hematopoietic cells 
[5,6,14]. 
The human prostate gland, unlike all other male sex acces-
sory tissues, has an extraordinary tendency towards growth 
disorders. In this gland, which is normally under androgen 
regulation, progression from normal epithelium to malignancy 
and metastasis may be associated with changes in the expres-
sion of specific growth factors and oncogenes that replace the 
need for androgens [15]. 
Over the past several years, a PTPase activity associated 
with prostatic acid phosphatase (PAcP) (orthophosphoric 
monoester phosphohydrolase, EC 3.1.3.2) has been identified 
in human prostate. This enzyme is a glycoprotein that con-
tains two 50 kDa subunits [16] and possesses phosphatase 
activity towards Tyr-phosphorylated proteins [17-19]. Re-
cently different groups have described the cloning and 
cDNA sequencing of human PAcP [20,21] showing that there 
are no significant sequence similarities between this phospha-
tase and the members of the PTPase family. They also have a 
different reaction mechanism. The importance of the normal 
and pathological growth-related processes in the prostate, to-
gether with the involvement of PTPases in these process, sup-
ports the notion that species of PTPases different from PAcP 
may be present in the prostate. However, so far, there is 
apparently little information about the spectrum of PTPases 
in the prostate. In the present study, we examine PTPase 
activity in the rat prostate gland. The results reveal the pres-
ence of a PTPase activity distinct from that associated with 
PAcP. The non-receptor PTPase, SHPl, which is present in 
very large amounts in the rat prostatic gland, is responsible, at 
least in part, for this activity. 
2. Materials and methods 
2.1. Materials 
Triton X-100, soybean trypsin inhibitor (STI), bovine serum albu-
min (fraction V), bacitracin, phenylmethylsulfonyl fluoride (PMSF), 
poly(Glu, Tyr) (4:1, by mass), ammonium molybdate (1% in 1.32 M 
HC1) and acid phosphatase kit were from Sigma (St. Louis, MO, 
USA). 
[32P]ATP and Western blotting detection system were from Dupont 
NEN (Boston, MA). Sephacryl S-300 HR was from Pharmacia (Upp-
sala, Sweden). Anti-human SHPl polyclonal antibody was from Up-
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state Biotechnology Inc. (Lake Placid, NY, USA) and anti-human 
PTP1B monoclonal was from Transduction Laboratories (Kentucky, 
USA). Protein standards for calibration of SDS electrophoretic gels, 
were obtained from Bio-Rad (Munich, Germany). RNAzol B was 
from Bioprobe (Montreuil/Bois, France). First strand cDNA synthesis 
kit was from Boehringer Mannheim (Germany). Taq polymerase was 
from Promega (Madison, WI, USA). Sense and antisense oligonucleo-
tides were synthesized and purified by Eurogentec (Seraing, Belgium). 
2.2. Preparation of the cytosolic and paniculate fractions 
Wistar rats were killed by decapitation. Pooled ventral prostates 
were homogenized in an Omni-Mixer with buffer (50 mM Tris-HCl, 
0.25 M sucrose, and 0.03% STI at pH 7.5). The homogenate was 
centrifuged at 150Xg for 5 min. The supernatant was centrifuged at 
lOOOOOXg for 1 h. The supernatant corresponded to the cytosolic 
fraction, and the pellet (paniculate fraction) was resuspended in 50 
mM Tris-HCl buffer (pH 7.5) containing 0.01% STI, 0.1 mM PMSF 
and 5% glycerol (buffer A). The paniculate fraction was then solubi-
lized using the same buffer with 1% Triton X-100. After stirring for 60 
min at 4°C, detergent-insoluble protein was removed by centrifugation 
at 400 000 Xg for 10 min. 
2.3. Concanavalin A-affinity chromatography 
The solubilized paniculate fraction was incubated with concanava-
lin A-Sepharose 4B, previously equilibrated with buffer A containing 
0.02% Triton X-100. The slurry was stirred slowly for 150 min at 4°C 
and then packed into a 10 X 1 cm chromatographic column. The un-
bound material was collected and assayed for PTPase and acid phos-
phatase activity. The column was washed exhaustively until no pro-
tein was detected eluting from the column. The retained material was 
eluted with the same buffer containing 0.6 M methyl-D-mannopyrano-
side (MM). Fractions were collected and separately assayed for 
PTPases and acid phosphatase activities. 
2.4. Assays for PTPase activity 
Phosphorylated poly(Glu,Tyr) was prepared by incubating 7.2 mg 
polymer with 1-2 mg of A-431 cell membranes, in 50 mM Tris-HCl 
buffer containing 0.1 |lM EGF, 250 uM [32P]ATP (700 dpm/pmol), 
100 uM orthovanadate, 5 mM MnCl2, and 10% NP-40 at pH 7.5, as 
previously described [22]. PTPase activity was measured by the release 
of [32P]phosphate from 32P-labelled poly(Glu,Tyr) in a 100 nl reaction 
mixture containing 30000 cpm 32P-labelled poly(Glu,Tyr) (final con-
centration 0.3 (J.M) and 8-15 ng sample in buffer containing 50 mM 
Tris-HCl, 0.1% albumin, 5 mM DTT, 0.01% STI, and 0.1 mM PMSF 
at pH 7 (PTPase buffer). The reaction was allowed to proceed for 
5 min at 30°C, then stopped by the addition of 100 |xl 30% trichloro-
acetic acid. The liberated inorganic [32P]phosphate was extracted us-
ing the molybdate extraction procedures and radioactivity was 
counted by liquid scintillation [22], 
2.5. Western immunoblotting and immunoprecipitation 
Samples (25 jxg) of different preparations were fractionated by SDS-
PAGE and electrotransferred to nitrocellulose membrane Hybond C. 
The blots were incubated either with anti-SHPl or with anti-PTPlB 
and the immunoreactive bands were detected by use of a horseradish 
peroxidase-conjugated secondary antibody and the enhanced chemi-
luminescence system from Dupont NEN. 
For immunoprecipitation, solubilized samples (500 |Xg) were incu-
bated with 4 |ig of antibody prebound to Sepharose protein A for 3 h 
at 4°C. The immunoprecipitate was collected by centrifugation, 
washed three times in buffer containing 50 mM Tris-HCl (pH 7), 
150 mM NaCl, 0.01% STI, 2 mM EDTA and 0.1 mM PMSF, and 
collected in Laemmli's sample buffer [23] for SDS-PAGE. The immu-
noprecipitation supernatant was also collected and immunoblotted 
using anti-SHPl antibody. 
2.6. Reverse transcription PCR 
RNA was extracted with the RNAzol B method. Total RNA (5 |ig) 
was denatured at 4°C for 10 min. cDNA was synthesized using a first 
strand cDNA synthesis kit. The reverse transcription mixture was 
diluted twofold with sterile water. PCR for SHP1, PTP1B and actin 
was then performed in a final volume of 50 |xl containing 5 JJ.1 of 
reverse transcribed total RNA, 2.5 units of Taq polymerase, specific 
sense and antisense primers (1 |xM), 250 |xM of dNTPs in 10 mM 
Tris-HCl buffer (pH 9) containing 50 mM KC1, 1.5 mM MgCl2, 
0.01% Triton X-100. Sense and antisense oligonucleotides derived 
from the cDNA sequence of SHP1, PTP1B and actin. The resulting 
cDNA amplification products for SHP1, PTP1B and actin were pre-
dicted to be 469, 398 and 517 bp in length, respectively. Thermal 
cycling parameters were 94°C for 1 min, 54°C for 1 min 30 s, 72°C 
for 3 min for 26 or 35 cycles with a final extension of 72°C for 10 min, 
in a Perkin Elmer thermal cycler. PCR products were separated on 
7.5% polyacrylamide gels and visualized with ethidium bromide. 
2.7. SHP1 immunohistochemistry 
Rat ventral prostate was fixed in 1.5% paraformaldehyde in 0.1 M 
phosphate buffer for 1 h 30 min. After fixation, prostatic fragments 
were dehydrated and embedded in paraffin and sections of 9 n,m thick 
were obtained. Then, sections were deparaffinized and treated with 
rabbit non-immune serum diluted 1:30 in Tris-HCl (0.05 M, pH 
7.6) for 30 min to reduce non-specific background staining. Sections 
were incubated overnight at 4°C with the same polyclonal antibody 
anti-SHPl used previously diluted 1:500. Following three 10 min 
washes, the sections were incubated for 1 h at 20°C in peroxidase-
conjugated goat anti-rabbit immunoglobulin (Sigma) at 1:100 dilution 
and rinsed twice. Peroxidase activity was revealed with 0.025%> DAB 
and 0.005%) H2O2 for 15 min, and then sections were washed with 
distilled water, dehydrated in graded concentrations of ethanol and 
mounted in Depex. Control sections were performed replacing the 
primary antibody by normal serum; these control sections showed 
no immunoreactive product. Some sections were also counterstained 
with 0.1% toluidine blue to facilitate the visualization of epithelial 
cells. 
2.8. Other procedures 
SDS-PAGE was performed according to Laemmli [23], The protein 
concentration was estimated by the method of Bradford [24] using 
bovine serum albumin as a standard. The acid phosphatase activity 
was determined colorimetrically using an acid phosphatase kit, with 
PNPP as substrate, as the manufacturer described. 
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Fig. 1. Concanavalin A affinity chromatography of solubilized par-
ticulate fraction. The procedures for this chromatography are de-
scribed in Section 2. The dotted line indicates the absorbance at 280 
nm. The column was washed until no protein could be detected in 
the eluate, and the glycoprotein was eluted with MM (arrow). Ali-
quots of each fraction were assayed for PNPase activity (upper pan-
el) and PTPase activity (lower panel), using PNPP and 
[32P]poly(Glu,Tyr) as substrates. The figure is representative of three 
experiments. The peaks of PTPase activity are designated I and II 
as indicated. 
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3. Results 2 3 4 
Using [32P]poly(Glu,Tyr) as substrate, we identified PTPase 
activity in the crude homogenate as well as in the lOOOOOXg-
supernatant and pellet derived from rat ventral prostate. 
Membrane and cytosolic fractions showed similar total 
PTPase activities, the specific activity being nearly twofold 
higher in the particulate fraction than in the cytosolic fraction, 
0.43 |a,mol/mg protein/min and 0.26 |a,mol/mg protein/min, re-
spectively. 
To further identify the prostatic PTPase activity, we at-
tempted to separate PTPase activity from that of acid phos-
phatase by concanavalin A-affinity chromatography. This lec-
tin has been successfully used previously for the purification 
of the PAcP [17,18]. When the solubilized particulate fraction 
was chromatographed on a concanavalin A-Sepharose 4B col-
umn, two peaks of PTPase activity were obtained (Fig. 1, 
lower panel). The fractions with higher PTPase activity, which 
was not bound to the lectin column, corresponded to peak I. 
The other peak, termed peak II, was retained by the resin and 
was eluted with methyl-D-mannopyranoside (MM). Both 
peaks exhibited PNPPase activity, but the PNPPase activity 
of peak II was at least 6-fold higher than that of peak I. On 
the other hand, the PTPase activity of peak I was at least 3-
fold higher than that of peak II. 
To further characterize the PTPase activity in peaks I and 
II, we tested a variety of potential modulatory agents of 
PTPase activity. The results are presented in Table 1. Firstly, 
peak I PTPase activity was examined for its sensitivity to the 
widely known PTPase inhibitors, sodium vanadate and acidic 
compounds such as non-phosphorylated poly(Glu,Tyr). Vana-
date and poly(Glu,Tyr), at 100 |J.M, inhibited this activity by 
81% and 69% respectively. Tartrate and fluoride, both inhib-
itory agents of PAcP activity, had no effect. The PTPase ac-
tivity was not inhibited by PNPP at 10 mM. We tested the 
effect of the same modulatory agents on PTPase and PNPPase 
activity of peak II. Both phosphatase activities were inhibited 
by vanadate and poly(Glu,Tyr). PTPase activity, however, 
appeared to be more sensitive to the inhibition induced by 
these two agents. The PNPPase activity was effectively inhib-
ited by NaF and slightly by tartrate whereas these agents had 
no effect on PTPase activity. If the dephosphorylation of 
[32P]poly(Glu,Tyr) observed in peak II was catalyzed by 
acid phosphatase, one would expect PNPP to inhibit this re-
action. As shown in Table 1, 10 mM PNPP inhibited the 
PTPase activity by 40%. Furthermore, we found that when 
[32P]poly(Glu,Tyr) was used as the substrate, peak II exhibited 
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Fig. 2. Detection of PTPase by Western blotting. Preparations ob-
tained from concanavalin A chromatography were subjected to 
SDS-PAGE, transferred to nitrocellulose membrane and Western-
blotted using anti-SHPl antibody. Revelation by a chemilumines-
cence-Western immunoblotting detection system is shown and corre-
sponds to the analysis of the solubilized particulate fraction (lane 
1), peak I (lane 2), peak II (lane 3) and bovine prostatic acid phos-
phatase (Sigma) (lane 4). In all cases, there are equal amounts of 
extract (25 |xg of protein). The figure is representative of three ex-
periments. The positions of the molecular mass markers are shown. 
a higher specific activity at neutral pH (0.009 nmol/mg/min) 
than at acidic pH (0.0012 nmol/mg/min) (data not shown). In 
marked contrast, PNPP hydrolysis was higher at acidic pH 
(data not shown). These findings suggest that peak II is, prob-
ably, due to PAcP. The peak I exhibiting high PTPase activity 
could represent a PTPase activity different from that associ-
ated with PAcP. 
Among the recently cloned PTPases, the 66 kDa phospho-
tyrosine phosphatase (SHP1) is expressed primarily in hema-
topoietic cells, but also in epithelial cells [5,6]. To test whether, 
at least in part, the PTPase activity detected in peak I is 
immunologically related to SHP1 we used a rabbit polyclonal 
antibody against this enzyme. Immunoblotting of the solubi-
lized particulate fraction showed that the antibody specifically 
recognized a 66 kDa protein (Fig. 2, lane 1). The pooled 
fractions of peaks I and II were also subjected to immuno-
blotting using the same antibody; the 66 kDa protein was 
again observed to be present in peak I (Fig. 2, lane 2) but 
not in peak II (Fig. 2, lane 3). The antibody did not recognize 
the partially purified bovine PAcP (Fig. 2, lane 4). 
To test the relative contribution of SHP1 to this PTPase 
Table 1 
Influence of various agents on PTPase activity of peak I and on PTPase and PNPPase of peak II 
Agent Concentration % of control 
Peak I Peak II 
[32P]poly(Glu,Tyr) pNPP [32P]poly(Glu,Tyr) 
Vanadate 
Poly(Glu,Tyr) 
Tartrate 
NaF 
pNPP 
1 uM 
100 uM 
100 irM 
1 mM 
10 mM 
10 mM 
10 mM 
19.3 
31 
104 
111 
83.9 
96.2 
62.2 
84.8 
98 
70.5 
37.3 
97 
54 
34 
114 
91 
119 
58 
The activities were measured as described in Section 2 in the presence of each of the agents at the indicated concentrations. The enzyme activity is 
expressed as a percentage of the control (in the absence of the agents). 
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Fig. 3. PTPase activity in SHP1 immunodepleted solubilized. A: Solubilized particulate fraction (PF) (500 |ig) was immunoprecipitated with 
anti-SHPl antibody (anti-PTP) or with preimmune control serum (PI) as described in Section 2. Supernatants of both immunoprecipitates were 
collected and were assayed for PTPase activity. Both supernatants were also incubated with concanavalin A and PTPase activity was measured 
in the unbound fractions (peak I). This figure is representative of three experiments. B: Immunoprecipitate (lane 1) and immunoprecipitation 
supernatant (lane 2) were subjected to SDS-PAGE, transferred to nitrocellulose membranes and Western-blotted using anti-SHPl antibody as 
described in Section 2. 
activity, the solubilized particulate fraction was immunopre-
cipitated with an anti-SHPl antibody and the PTPase activity 
present in the original and immunodepleted solubilized frac-
tion was measured. As shown in Fig. 3A, the immunodeple-
tion of SHP1 produced a loss of 51.4% of the PTPase activity. 
The loss of PTPase activity was very similar when both frac-
tions were incubated with concanavalin A and the PTPase 
activity was measured in the fractions (peak I) unbound to 
the lectin. The absence of SHP1 in the immunodepleted solu-
bilized fraction was tested by immunoblot (Fig. 3B, lane 2). 
This enzyme was present in the immunoprecipitated fraction 
(Fig. 3B, lane 1) as probed by immunoblotting. 
In the particulate fraction and in peak I but not in peak II 
(Fig. 2), anti-SHPl antibody also recognized a major band at 
63 kDa and a minor band at 50 kDa. The 50 kDa band could 
be due to PTP1B, another ubiquitously expressed non-recep-
tor PTPase, which could also contribute peak I PTPase activ-
ity. Given the homology between various PTPases, it is pos-
sible that the SHP1 antibodies cross-react with PTP1B. Thus, 
peak I was also subjected to immunoblotting using an anti-
PTP1B antibody. The results obtained showed that the 
amount of PTP1B was very low (data not shown). We could 
also think that the 63 and 50 kDa band could correspond to 
proteolytic fragments of SHP1. To examine this possibility, 
immunoblotting, using anti-SHPl antibodies, was next carried 
out on the pellet and supernatant obtained after centrifuga-
tion of the particulate fraction and on the cytosolic fraction. 
As shown in Fig. 4A, three immunoreactive bands of 66, 63 
and 50 kDa were observed in the particulate and cytosolic 
fractions. The corresponding scanning densitometry of immu-
noreactive bands (Fig. 4B) allowed for estimating the relative 
contents of all three bands in the different fractions. In the 
particulate fraction, the 66 kDa form was the predominant 
one, with the intensity pattern 66 > 63 » 50 kDa. However, in 
the cytosolic fraction the relative contents of the three bands 
were very similar. After centrifugation of the particulate frac-
tion, a relocalization of the three forms from the particulate to 
the soluble fraction was observed. The 63 and 50 kDa bands 
were no longer present in the pellet, being located in the 
supernatant, whereas the 66 kDa band was present in both 
fractions but its amount was twofold higher in the soluble 
fraction than in the pellet. Centrifugation of the particulate 
fraction also resulted in activation of prostatic PTPase activ-
ity. About 50% of the PTPase activity was recovered in the 
pellet, the remainder being in the supernatant. The enzyme 
present in the supernatant exhibited a higher specific PTPase 
activity: 1.30 nmol/mg/min in the supernatant and 0.19 nmol/ 
mg/min in the pellet. Limited digestion of the particulate frac-
tion with trypsin increased the PTPase activity by approxi-
mately twofold but had little effect on the PTPase activity 
in the cytosolic fraction (data not shown). 
The presence of SHP1 and PTP1B mRNA in rat ventral 
prostate was demonstrated using reverse transcription PCR 
(Fig. 5). It is clear that the expression of SHP1 mRNA was 
higher than that of PTP1B, according with the amount of 
both proteins detected by immunoblotting. 
SHP1 expression in the rat prostate gland was examined 
using immunohistochemistry of paraffin-embedded sections. 
The prostatic epithelium showed positive SHP1 immunostain-
ing (Fig. 6b,c). The SHP1 immunoreactivity was restricted to 
the epithelial cells of the prostate and blood vessels and was 
not found in the stromal cells or elsewhere in the prostate 
gland. 
4. Discussion 
In the last decade, besides the identification of PTPases as 
enzymes distinct from other classes of protein phosphatases 
by their specificity and their high activity towards protein 
phosphotyrosyl residues, it has become evident that all 
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PNPP phosphatases in animal tissues may act upon P-Tyr 
protein. In the case of the human prostate, it has been ob-
served that highly purified preparations of acid phosphatase 
show dephosphorylating activity on Tyr-phosphorylated pro-
teins [17-19]. In this study, we show that the rat prostate 
possesses a PTPase activity different from that associated 
with PAcP. SHP1 is one of the principal factors responsible 
for this activity. This was supported by several observations: 
we detected the presence of SHP1 by Western blotting in 
fractions depleted of PAcP; immunodepletion of SHP1 re-
sulted in a considerable loss of PTPase activity; mRNA for 
SHP1 was detected by reverse transcription PCR; and finally, 
we found that SHP1 is localized within the epithelial cells, 
mainly in the apical zone. Thus, the SHP1 detected is specif-
ically expressed in rat prostate gland and is not due to con-
taminating blood cells. Other PTPases can contribute to this 
activity but probably to a lesser extent than SHP1. 
Li et al. [17] have described that the predominant form of 
active PTPase in human prostate is due to acid phosphatase 
and that during the purification processes, no PTPase activity 
could be detected other than that exhibiting optimum acidic 
26 35 
SHPTP1 
PTP1B 
Actin 
Fig. 5. Espression of PTP1B and SHP1 mRNA in rat ventral pros-
tate. PCR was performed on total RNA as described in Section 2 
and the products were revolved on a 7.5% polyacrylamide gel. 
Numbers 26-35 refer to PCR cycle number. 
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Fig. 4. Detection of SHP1 by Western immunoblotting following 
centrifugation of the particulate fraction. A: Equal amounts of ex-
tract (25 |xg) were subjected to SDS-PAGE and analyzed by West-
ern blotting using anti-SHPl antibody. Revelation by an enhanced 
chemiluminescence-Western-immunoblotting detection system is 
shown. Lanes 1, 2, 3 and 4 correspond to the particulate fraction, 
pellet and supernatant obtained following centrifugation of the par-
ticulate fraction and the cytosolic fraction, respectively. This figure 
is representative of three experiments. B: Videodensitometric analy-
sis of the immunoblot. 
pH and sensitivity to inhibition by L(+) tartrate. Similar re-
sults were obtained by Lin and Clinton in human seminal 
plasma [18]. It is possible that the differences observed with 
our results may be related to the different conditions for the 
measurement of PTPase activity or to the species used. 
In addition to SHP1, the anti-SHPl antibody also recog-
nized two other proteins of different molecular sizes: 63 and 
50 kDa, which probably correspond to proteolytic fragments 
of the 66 kDa form. The three molecular forms were present 
in the particulate and cytosolic fractions derived from rat 
prostate. However, the three forms were more abundant in 
the cytosolic fractions than in the particulate fraction. A re-
localization of the immunoreactive forms from the particulate 
to the soluble fraction, with an increase in the amount of the 
lower molecular size immunoreactive forms, was observed 
following centrifugation of the particulate fraction. This was 
associated with an increase in PTPase activity. The limited 
proteolysis of the particulate fraction also resulted in a con-
siderable increase in catalytic activity. This indicates that both 
trypsinization and centrifugation generated soluble, smaller 
and more active SHP1 forms. In a recent study, Zhao et al. 
[25] reported that a fragment containing 41 amino acids can 
be cleaved from the C-terminus of SHP1, leaving a trypsin-
resistant core of 63 kDa. This truncation was accompanied by 
an increase in catalytic activity. A similar increase in activity 
of the pancreatic PTPase [22] and PTP1B [4] was observed 
following truncation of a C-terminal fragment of these en-
zymes. The fractions of the C-terminal regions of non-trans-
membrane PTPases are largely unknown. The C-terminal re-
gion of PTP1B has recently been shown to anchor this protein 
at the membrane of the endoplasmic reticulum [26]. T-cell 
PTP has been shown to bind DNA in vitro through its C-
terminal region [27]. In the case of SHP1, the C-terminal seg-
ment seems to play a regulatory role. Recent experiments have 
reported an increase in the catalytic activity of SHP1 follow-
ing phosphorylation of Tyr538 in the C-terminal region in 
response to growth factors [28,29]. The low efficiency of tryp-
sin on PTPase activity in the cytosolic fraction is striking, 
although the amount of SHP1 was similar to that of the 
particulate fraction. In vitro studies have shown that anionic 
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poietic cells, notably in malignant epithelial cell lines [7,14] 
and in tissues that are actively replenished from stem cells 
[32], suggesting that this enzyme plays a role in cell growth 
or differentiation. Such a role has been recently demonstrated 
in interleukin-3-dependent hematopoietic cells [13] and fibro-
blasts [33] in which the overexpression of SHPl reduced the 
cell growth rate. 
In conclusion, our study shows, for the first time, the pres-
ence of a PTPase activity different from that associated with 
PAcP in the rat prostate gland. This PTPase activity is due, at 
least in part, to SHPl. The two PTPase activities can be 
separated by affinity chromatography using concanavalin A. 
The identification of SHPl in the prostate gland makes it 
necessary to analyze the importance of its activity in vivo 
and its relation with the prostatic growth and differentiation 
processes. 
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